Share This Page
Drug Price Trends for CARDIZEM LA
✉ Email this page to a colleague
Average Pharmacy Cost for CARDIZEM LA
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CARDIZEM LA 120 MG TABLET | 00187-2045-30 | 3.64674 | EACH | 2025-09-17 |
| CARDIZEM LA 120 MG TABLET | 00187-2045-90 | 3.64674 | EACH | 2025-09-17 |
| CARDIZEM LA 120 MG TABLET | 00187-2045-90 | 3.65223 | EACH | 2025-08-20 |
| CARDIZEM LA 120 MG TABLET | 00187-2045-30 | 3.65223 | EACH | 2025-08-20 |
| CARDIZEM LA 120 MG TABLET | 00187-2045-30 | 3.65223 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
CARDIZEM LA Market Analysis and Price Projections
What Is the Current Market Position of CARDIZEM LA?
CARDIZEM LA (diltiazem hydrochloride extended-release capsules) is a calcium channel blocker prescribed for hypertension, angina, and arrhythmias. It has been marketed since 1991 by Biovail (now part of Pfizer). Its approval spans multiple regions, including the U.S., Europe, and Japan.
The drug remains a significant player in hypertension and angina segments due to its efficacy and established safety profile. The global calcium channel blocker market was valued at approximately USD 2.35 billion in 2022, with CARDIZEM LA representing roughly 10-15% of this based on sales reports and market share estimates.
Key competitors include Norvasc (amlodipine), Cardizem (immediate-release diltiazem), and other extended-release formulations like Tiazac. The segment is mature with limited growth, but steady demand persists, especially in North America and Europe.
What Are the Key Market Drivers and Challenges?
Drivers:
- Rising prevalence of hypertension and cardiovascular diseases globally.
- Physician familiarity and established efficacy.
- Extended-release formulations offer improved adherence.
Challenges:
- Competition from generic formulations reduces prescriber loyalty and price.
- Patent expiration timelines influence market share.
- Price sensitivity in public and private healthcare sectors.
How Has Patent and Regulator Landscape Affected Market Dynamics?
The original patent on CARDIZEM LA expired in 2010 in the U.S., opening pathways for generics. Multiple generic versions entered the market, leading to price erosion. Pfizer's exclusivity on specific extended-release formulations may have extended market control locally until patent challenges.
Regulatory pathways for biosimilars are less relevant, but approval of competing drugs influences competitive intensity. Clinical guidelines consistently recommend CARDIZEM LA for specific indications, maintaining its clinical relevance.
What Are the Pricing Trends and Projections?
Current Pricing (U.S. Market)
- Brand name CARDIZEM LA: USD 400–USD 550 for a 30-count bottle (30 mg, 60 mg, 120 mg doses).
- Generics: USD 150–USD 250 for similar volumes.
- The price difference persists due to brand recognition and prescribing habits.
Price Trends (2018–2022)
- Brand price declined 10–15% annually due to generic entry.
- Generic prices stabilized after initial competition, with some pricing flexibility in retail and institutional settings.
- The impact of inflation-adjusted manufacturing costs remains low due to high market penetration.
Projected Price Range (Next 5 Years)
- Generics are expected to dominate, with prices remaining in the USD 150–USD 250 range.
- Brand price likely to stay above USD 350 due to limited new formulations or modifications.
- Market consolidation and potential biosimilar entry could suppress prices further.
Regional Variations
- In Europe, prices are generally 20–30% lower due to price regulation.
- In Japan, pricing remains stable with government controls, averaging USD 300–USD 400 for branded versions.
What Is the Future Outlook?
Market Size and Growth
- Overall market growth for calcium channel blockers is forecast at 2% annually until 2027.
- CARDIZEM LA will retain niche market share due to its use in specific patient groups.
- Increased focus on combination therapies could influence demand, but not significantly.
Price Evolution Factors
- Patent litigations and potential patent extensions may temporarily impact pricing.
- Policy changes favoring biosimilar and generic adoption pressure brand prices downward.
- New formulations or indications could bolster pricing power temporarily.
Investment and R&D Considerations
- Limited pipeline development for the same molecule indicates stable but mature market.
- R&D investment likely directed toward new delivery systems or combination therapies.
- Strategic partnerships or licensing may influence regional pricing strategies.
Key Takeaways
- CARDIZEM LA is a mature product with declining brand prices post-generic entry.
- US generic prices hover around USD 150–USD 250; branded versions stay above USD 350.
- Industry trend points to stable generic prices with potential further decreases due to market competition.
- Patent expiries and regulatory changes significantly influence pricing dynamics.
- The global market is expected to grow modestly, with CARDIZEM LA maintaining niche relevance.
5 FAQs
-
When did the patent on CARDIZEM LA expire?
Patent expiration in the U.S. was in 2010, leading to multiple generic versions entering the market. -
What are the main competitors to CARDIZEM LA?
Immediate-release diltiazem (Cardizem), amlodipine (Norvasc), and other extended-release calcium channel blockers. -
How does generic pricing compare to brand pricing?
Generics are roughly 50–60% cheaper, typically USD 150–USD 250, versus USD 400–USD 550 for branded versions. -
What regional factors influence CARDIZEM LA pricing?
Price regulation in Europe reduces prices by 20–30%. Japan maintains stable prices due to government controls. -
What is the outlook for new formulations?
Limited pipeline development exists; future innovations likely focus on combination therapies or delivery advances rather than new versions of CARDIZEM LA.
References
[1] MarketWatch. (2023). Calcium channel blocker market size and forecast.
[2] IQVIA. (2022). U.S. prescription trends for calcium channel blockers.
[3] Pfizer. (2022). Cardizem LA product monograph.
[4] European Medicines Agency. (2022). Medication pricing and reimbursement overview.
[5] Industry Reports. (2022). Generic drug pricing and market share analysis.
More… ↓
